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Introduction
Pharmacokinetic (PK) of drugs in critically ill patients
could vary from the general population. Patients
undergoing hemodiafiltration (HDF) could present
lower linezolid (LZ) concentration than expected. The
pharmacokinetic/pharmacodynamic analysis (PK/ PD)
is a useful tool to optimize dosing regimens of antibio-
tic therapy.
Objectives
To evaluate the efficacy and safety of LZ for the treat-
ment of infections caused by gram-positive microorgan-
isms (GPM) in the Intensive Care Unit (ICU) patients
undergoing HDF using a PK/PD analysis and Monte
Carlo simulation (MCS).
Methods
Study developed in three tertiary hospitals in patients
with severe sepsis, HDF and treatment with LZ (600mg
q12h). 8 each patient blood (prefilter and postfilter) and
ultrafiltrate samples were taken. Concentrations of line-
zolid were determined by HPLC-UV. PK analysis and
MCS were performed using Phoenix WinNonlin Version
6.3 (Pharsight) and Oracle Crystal Ball programs to
assess the probability of successful treatment (PST)
[area under the curve (AUC24)/MIC> 100 for different
MICs], the probability of Cmin>2 mg/L and the risk of
overexposure (RO) [Cmin> 10 mg /L and/or AUC24>
400 mg * h/L] at doses of 600mg q12 and q8h. Patients
were grouped by liver and renal function considering
impaired liver function (ILF) the elevation> 2 times
transaminase and/or elevated bilirubin and severe renal
dysfunction (SRD) the presence of CrCl < 15 ml/min.
Group (G) 0: both normal, G1: ILF or SRD, G2: both.
Quantitative variables were expressed as mean and stan-
dard deviation (SD), qualitative as percentages. a signifi-
cance level of 0,05.
Results
26 patients were included. The AUC 24 (mg * h / L)
was: G0 111 (SD 39), G1 155 (SD 79) and G2 246
(SD64), the Cmin (mg/L) was: G0 1,5 (SD 1,2), G1 2,5
(SD 1,8) and G2 4,6 (SD 2) and the clearance (Cl) (L/h)
was: G0 12 (SD 4), G1 10,1 (SD 5,9) and G2 8,9 (SD
5,1). The PST was 96, 81, 38 and 0% for GPM with
MICs of 0,5, 1, 2 and 4 mg/L. In the MCS, 600 mg
12qh ensures PST> 80% for MIC ≤1mg/L in the pre-
sence of some dysfunction (G1 and G2), increasing to>
90% for all groups with 600 mg q8h without RO. In the
G2, the current dose assures PST> 70% for MIC of 2,
increasing to >90% with 600mg q8h but with high RO
(> 30%). No amount is effective for MIC ≥4 mg/L. The
probability of Cmin >2 mg/L was 23, 33 and 85% for G0,
G1 and G2 respectively, increasing to 60% in G0 and
G1 with 600 mg q8h (see summary table in Figure 1).
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Conclusions
In patients with RRT, 600 mg q12h guarantees PST >80%
for MIC ≤1 in the presence of SRD and/or ILF. For this
MIC, 600 mg q8h guarantees high PST in all patients and
increases the probability of Cmin> 2. For MGP with MIC
of 2, only in the presence of both dysfunctions is possible
achieving the PK/PD target.
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